Mauritania vs Singapore: HIV/AIDS deaths averted by antiretroviral therapy
HIV/AIDS deaths averted by antiretroviral therapy over time
- Mauritania
- Singapore
How they compare
Singapore currently reports 331.57 deaths against 277.42 deaths in Mauritania, a difference of 54.15 deaths.
That makes Singapore's figure about 1.2 times Mauritania's.
The two have swapped places 2 times across 34 shared years of data; in 1990 it was Singapore ahead.
Mauritania ranks 103rd and Singapore ranks 102nd of 157 countries.
Across the 4 decades both report, Mauritania averaged higher in 2 and Singapore in 2.
Head to head by decade
| Decade | Mauritania | Singapore | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0.6975 deaths | 0.6975 deaths | Singapore |
| 2000s | 89.77 deaths | 53.47 deaths | 36.3 deaths | Mauritania |
| 2010s | 261.27 deaths | 253.24 deaths | 8.03 deaths | Mauritania |
| 2020s | 276.81 deaths | 336.06 deaths | 59.25 deaths | Singapore |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Mauritania or Singapore?
- Singapore, at 331.57 deaths against 277.42 deaths in Mauritania as of 2023.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Mauritania and Singapore?
- 54.15 deaths, with Singapore ahead.
- How many years of comparable data are there for Mauritania and Singapore?
- 34 years are reported by both, from 1990 to 2023.
- How do Mauritania and Singapore rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Mauritania ranks 103rd and Singapore ranks 102nd of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.